Document is current
Any future updates will be listed below
-
Authors
Reidy, Kimberly J. https://orcid.org/0000-0002-7680-457X
Guillet, Ronnie https://orcid.org/0000-0003-4394-344X
Selewski, David T. https://orcid.org/0000-0003-0358-0760
Defreitas, Marissa
Stone, Sadie https://orcid.org/0000-0003-2507-3903
Starr, Michelle C. https://orcid.org/0000-0001-9412-8950
Harer, Matthew W. https://orcid.org/0000-0001-5493-3269
Todurkar, Namrata
Vuong, Kim T. https://orcid.org/0000-0001-9177-819X
Gogcu, Semsa https://orcid.org/0000-0002-0429-9404
Askenazi, David
Tipple, Trent E. https://orcid.org/0000-0002-5156-4282
Charlton, Jennifer R. https://orcid.org/0000-0002-2225-535X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK136989, R01DK136989)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
- License Information
-
More Information
Article History
Received: 15 April 2024
Revised: 21 May 2024
Accepted: 6 June 2024
First Online: 5 July 2024
Competing interests
: All authors declare no real or perceived conflicts of interest that could affect the study design, collection, analysis and interpretation of data, writing of the report, or the decision to submit for publication. Reidy: no relevant disclosures, Board Member of Neonatal Kidney Collaborative and site PI for Travere Therapeutics study. Guillet: no relevant disclosures, Board Member of Neonatal Kidney Collaborative, investor in Zorro-Flow. Selewski: no relevant disclosures, Board Member of Neonatal Kidney Collaborative. Defreitas: no relevant disclosures. Stone: no relevant disclosures, Neonatal Clinical Consultant for Lexicomp. Starr: no relevant disclosures, Board Member of Neonatal Kidney Collaborative. Harer: no relevant disclosures, Board Member of Neonatal Kidney Collaborative. Todurkar: no relevant disclosures. Vuong: no relevant disclosures. Gogcu: no relevant disclosures. Askenazi: no relevant disclosures, Board Member of Neonatal Kidney Collaborative; In the last 24 months, David J Askenazi has consulted with Nuwellis, Seastar, and Abbott. Over the last 24 months, his institution has received funding for education and research that is not related to this project from Nuwellis, Bioporto, Leadiant and Seastar. He has financial interests in patent/innovations pending in the area of kidney support therapies and urine collection devices. He is the Founder and Chief Scientific Officer for Zorro-Flow Inc. Tipple: no relevant disclosures, Board Member of Neonatal Kidney Collaborative. Charlton: no relevant disclosures, Board Member of Neonatal Kidney Collaborative, investor in Zorro-Flow.
